190 related articles for article (PubMed ID: 15907448)
1. Tuftsin-mediated immunoprophylaxis against an isolate of Aspergillus fumigatus shows less in vivo susceptibility to amphotericin B.
Khan MA; Ahmad N; Moin S; Mannan A; Wajahul H; Pasha ST; Khan A; Owais M
FEMS Immunol Med Microbiol; 2005 Jun; 44(3):269-76. PubMed ID: 15907448
[TBL] [Abstract][Full Text] [Related]
2. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
Khan MA; Owais M
J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
[TBL] [Abstract][Full Text] [Related]
3. Co-administration of immunomodulator tuftsin and liposomised nystatin can combat less susceptible Candida albicans infection in temporarily neutropenic mice.
Khan MA; Nasti TH; Saima K; Mallick AI; Firoz A; Wajahul H; Ahmad N; Mohammad O
FEMS Immunol Med Microbiol; 2004 Jul; 41(3):249-58. PubMed ID: 15196575
[TBL] [Abstract][Full Text] [Related]
4. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice.
Khan MA; Nasti TH; Owais M
J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780
[TBL] [Abstract][Full Text] [Related]
5. Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.
Warn PA; Morrissey G; Morrissey J; Denning DW
J Antimicrob Chemother; 2003 Apr; 51(4):913-9. PubMed ID: 12654746
[TBL] [Abstract][Full Text] [Related]
6. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
Manavathu EK; Cutright JL; Chandrasekar PH
Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
[TBL] [Abstract][Full Text] [Related]
7. Prophylactic use of liposomized tuftsin enhances the susceptibility of Candida albicans to fluconazole in leukopenic mice.
Khan MA; Khan A; Owais M
FEMS Immunol Med Microbiol; 2006 Feb; 46(1):63-9. PubMed ID: 16420598
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulator tuftsin augments anti-fungal activity of amphotericin B against experimental murine candidiasis.
Masood AK; Faisal SM; Haque W; Owais M
J Drug Target; 2002 May; 10(3):185-92. PubMed ID: 12075819
[TBL] [Abstract][Full Text] [Related]
9. Immunomodulator tuftsin increases the susceptibility of Cryptococcus neoformans to liposomal amphotericin B in immunocompetent BALB/c mice.
Khan MA; Owais M
J Drug Target; 2005 Aug; 13(7):423-9. PubMed ID: 16308211
[TBL] [Abstract][Full Text] [Related]
10. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191.
Graybill JR; Kaster SR
Am Rev Respir Dis; 1984 Feb; 129(2):292-5. PubMed ID: 6364905
[TBL] [Abstract][Full Text] [Related]
11. Use of tuftsin bearing nystatin liposomes against an isolate of Candida albicans showing less in vivo susceptibility to amphotericin B.
Khan MA; Syed FM; Nasti HT; Saima Dagger K; Haq W; Shehbaz A; Owais M
J Drug Target; 2003 Feb; 11(2):93-9. PubMed ID: 12881195
[TBL] [Abstract][Full Text] [Related]
12. Combination therapy with micafungin and amphotericin B for invasive pulmonary aspergillosis in an immunocompromised mouse model.
Nagasaki Y; Eriguchi Y; Uchida Y; Miyake N; Maehara Y; Kadowaki M; Harada M; Akashi K; Shimono N
J Antimicrob Chemother; 2009 Aug; 64(2):379-82. PubMed ID: 19465436
[TBL] [Abstract][Full Text] [Related]
13. Antifungal prophylaxis is effective against murine invasive pulmonary aspergillosis.
Rieg G; Spellberg B; Schwartz J; Fu Y; Edwards JE; Sheppard DC; Ibrahim AS
Antimicrob Agents Chemother; 2006 Aug; 50(8):2895-6. PubMed ID: 16870798
[No Abstract] [Full Text] [Related]
14. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B.
Paterson PJ; Seaton S; Prentice HG; Kibbler CC
J Antimicrob Chemother; 2003 Nov; 52(5):873-6. PubMed ID: 14519673
[TBL] [Abstract][Full Text] [Related]
15. Tuftsin-bearing liposomes as drug vehicles in the treatment of experimental aspergillosis.
Owais M; Ahmed I; Krishnakumar B; Jain RK; Bachhawat BK; Gupta CM
FEBS Lett; 1993 Jul; 326(1-3):56-8. PubMed ID: 8325389
[TBL] [Abstract][Full Text] [Related]
16. Safety, efficacy and pharmacokinetics of tuftsin-loaded nystatin liposomes in murine model.
Khan MA; Faisal SM; Mohammad O
J Drug Target; 2006 May; 14(4):233-41. PubMed ID: 16777682
[TBL] [Abstract][Full Text] [Related]
17. Prophylactic administration of liposomal amphotericin B is superior to treatment in a murine model of invasive aspergillosis after hematopoietic cell transplantation.
BitMansour A; Brown JM
J Infect Dis; 2002 Jul; 186(1):134-7. PubMed ID: 12089676
[TBL] [Abstract][Full Text] [Related]
18. Comparative study on the efficacy of AmBisome and Fungizone in a mouse model of pulmonary aspergillosis.
Takemoto K; Yamamoto Y; Ueda Y; Sumita Y; Yoshida K; Niki Y
J Antimicrob Chemother; 2006 Apr; 57(4):724-31. PubMed ID: 16446374
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
Verweij PE; Oakley KL; Morrissey J; Morrissey G; Denning DW
Antimicrob Agents Chemother; 1998 Apr; 42(4):873-8. PubMed ID: 9559799
[TBL] [Abstract][Full Text] [Related]
20. Pulmonary aspergillosis in mice: treatment with a new triazole SCH39304.
Defaveri J; Salazar MH; Rinaldi MG; Graybill JR
Am Rev Respir Dis; 1990 Sep; 142(3):512-5. PubMed ID: 2202244
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
